TCL Archive Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer November 28, 2014
TCL Archive DCBDC Bard Approves Expansion Of SPORE Program To GY Cancers; Okays Two other RFAs December 4, 1992
TCL Archive Sharp Increase In Cancer Mortality Could Bring Drastic Program Changes; All 1975 Data Needed December 12, 1975